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Summary The relationship between female hormone use and primary liver cancer was analysed using data
from a case-control study conducted between 1984 and 1992 in Milan on 82 female incident cases with
histologically or serologically confirmed hepatocellular carcinoma and 368 controls admitted to hospital for
acute non-neoplastic, non-hormone-related diseases. An elevated relative risk (RR) or primary liver cancer was
observed in oral contraceptive (OC) users (RR 2.6, for ever versus never users, 95% confidence interval, CI
1.0-7.0). The RR was directly related to duration of use (RR 1.5 for A5 years and 3.9 for >5 years) and
persisted for longer than 10 years after stopping use (RR 4.3%, 95% CI 1.0- 18.2). The RR were below unity,
although not significantly, for women ever using oestrogen replacement therapy (RR 0.2, 95% CI 0.03-1.5)
and female hormones for indications other than contraception and menopausal therapy (RR 0.4, 95% CI
0.1-1.5). The long-lasting, association between risk of hepatocellular carcinoma and OC use has potential
implications on a public health scale, since primary liver cancer is a relatively rare disease among young
women, but much more common at older ages. This study provides limited but reassuring evidence on the
possible relationship between oestrogen replacement treatment and subsequent risk of hepatocellular car-
cinoma.
There is evidence from several case-control studies of a
positive association between the use of oral contraceptives
(OC) and primary liver cancer in developed countries
(Henderson et al., 1983; Neuberger et al., 1986; Forman et
al., 1986; La Vecchia et al., 1989; Palmer et al., 1989; Yu et
al., 1991; Hsing et al., 1992; Trichopoulos, 1992; WHO,
1992), although data are inconsistent for developing coun-
tries (WHO, 1989). This association is biologically plausible,
as OCs are promoters of hepatocarcinogenesis in rodents
(Yager & Yager, 1980) and the pill is known to increase the
risk of adenoma of the liver in humans (Baum et al., 1973;
Mettlin & Natarajan, 1981).
In Italy, mortality from primary liver cancer in women
below age 45 is extremely low, although some upward trend
between the 1950s and the 1980s has been observed in young
women, but not in young men (Decarli & La Vecchia, 1984).
This may support an involvement of OC use in the
pathogenesis of this cancer. A case-control study found a
significantly increased risk of hepatocellular carcinoma in
Italian women 32-59, who had used the pill for longer than
5 years (La Vecchia et al., 1989).
This paper is an update of that study and is meant to
quantify the risk of OC use with reference not only to
duration of use, but also to time since last use. Oestrogen
replacement treatment and female hormones for indications
other than contraception and menopausal therapy are also
considered.
Subjects and methods
Data are derived from an ongoing case-control study of
several digestive tract neoplasms, based on a network of
teaching and general hospitals in the greater Milan area (La
Vecchia et al., 1987; La Vecchia et al., 1988). Between
January 1984 and February 1992, 82 female incident cases
(aged 28-73, median age 59 years) of histologically or
serologically confirmed primary liver cancer were interviewed
using a structured questionnaire, including information on
socio-demographic indicators, personal characteristics and
habits, selected dietary factors, a problem-oriented medical
history and use of selected drugs, including oral contracep-
tives, non-contraceptive oestrogens for menopausal replace-
ment treatment and female hormones for other indications.
The comparison group consisted of 368 women (aged 26-76,
median aged 59 years), admitted to hospital for a wide
spectrum of acute non-neoplastic diseases (37% traumas,
13% other orthopaedic disorders, 40% acute surgical condi-
tions, 10% other miscellaneous diseases). Since none of the
women aged 60 or over had ever used OC, the analysis for
OC was limited to women aged less than 60 years.
Relative risks (RR) of liver cancer and the corresponding
95% confidence intervals (CI) in relation to OC, oestrogen
replacement treatment and female hormones for other indica-
tions were estimated, after adjustment for age, by the method
described by Mantel and Haenszel (1959); for multiple levels
of exposure, the significance of the linear trend in risk was
assessed by the Mantel test (Breslow & Day, 1980). Uncondi-
tional multiple logistic regression, fitted by the method of
maximum likelihood, was used to allow for possible
confounding factors (Breslow & Day, 1980). The regression
models included terms for age, education, parity and, in turn,
ever use of OC, duration of use and time since last use.
Further inclusion in the regression models of terms for
alcohol and tobacco (which were not significantly related to
hepatocellular carcinoma in Italian women) did not appreci-
ably modify any of the estimates.
Results
Various measures of OC use in women below age 60 are
considered in Table I. A total of nine (21%) cases and 21
(11%) controls had ever used the pill. The corresponding RR
was 2.3 (95% CI 1.0-5.4). The risk increased with duration,
with RRs of 1.5 for a use of < 5 years and 2.6 for longer
use. The RR was 1.2 (95% CI 0.3-4.9) in women who had
stopped OC use 10 years before or less, but was significantly
elevated for those who had stopped more than 10 years
earlier (RR 3.5, 95% CI 1.0-12.0). These risk estimates did
not appreciably change after allowance for age, education
and parity.
Relative risks for use of oestrogen replacement therapies
and female hormones for other indications are reported in
Table II. One case (1%) versus 19 (5%) controls had ever
used oestrogens for post-menopausal symptoms; correspond-
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Table 1 Frequencies and relative risk of primary liver cancer in relation of various measures of oral
contraceptive use. Milan, Italy, 1984-92
Oral contraceptive Hepatocellular Relative risk estimates (95% CI)
use carcinoma Controls M-Ha Multivariateb
Never 34 173 lC IC
Ever 9 21 2.3 2.6
(1.0-5.4) (1.0-7.0)
Duration of use (years)d
45 years 5 17 1.5 1.5
(0.5-4.5) (0.5-5.0)
>5 years 2 4 2.6 3.9
(0.5-13.7) (0.6-24.5)
X2 (trend) 4.38e 4.06e
Time from last use (years)d
A10 years 3 12 1.2 1.1
(0.3-4.9) (0.3-4.6)
>10 years 4 6 3.5 4.3
(1.0-12.0) (1.0-18.1)
aMantel-Haenszel estimates adjusted for age. bEstimates from multiple logistic regression; allowance
was made for age, education and parity. cReference category. dThe sum does not add up to the total of
users because of missing values; ep<0.05.
Table I1 Frequencies and relative risk of primary liver cancer in relation to use of
non-contraceptive female hormones. Milan, Italy, 1984-92
Hepatocellular Relative risk estimatesa
Type of hormone carcinoma Controls (95% CI)
Oestrogens replacement
therapies
never 81 349 lb
ever 1 19 0.2
(0.03-1.5)
Female hormones for
other indications
never 80 344 lb
ever 2 24 0.4
(0.1-1.5)
"Mantel-Haenszel estimates adjusted for age. bReference category.
ing numbers for other female hormones were two (2%) cases
and 24 (7%) controls. None of the RRs were significant,
though the risk estimates were below unity (0.2 for oestrogen
replacement therapies and 0.4 for other female hormones).
Discussion
The results of this case-control study confirm an increased
risk of primary liver cancer in OC users (Henderson et al.,
1983; Neuberger et al., 1986; Forman et al., 1986; La Vecchia
et al., 1989; Palmer et al., 1989; Yu et al., 1991; Hsing et al.,
1992; Trichopoulos, 1992; WHO, 1992), and, more import-
antly, indicate that the risk persists for 10 or more years after
stopping treatment.
Primary liver cancer in Italy is relatively rare among young
women, but much more common in older age groups
(Decarli & La Vecchia, 1984). Thus, the finding that the risk
persists so long after stopping OC use has relevant implicat-
ions on a public health scale, as the risk remains high at ages
at which hepatocellular carcinoma becomes more frequent.
The observation of the time pattern of the risk of OC is
not consistent with a promotional and, hence, rapidly emerg-
ing effect. Conversely the long-lasting influence of OC use on
risk of hepatocellular carcinoma is similar to that described
for pregnancy and birth (Trichopoulos, 1992; Stanford et al.,
1992; Tzonou et al., 1992; Le Vecchia et al., 1992),
confirming that the effect of contraceptives on the risk of
several neoplasms compares well to that of pregnancy (La
Vecchia et al., 1990).
Our findings that oestrogen replacement therapies and use
of female hormones for other indications do not enhance the
risk of liver cancer are in agreement with those of a Swedish
cohort study (Adami et al., 1989) which, on the basis of 13
cases, suggested that hormone replacement therapy was
inversely associated with cancer of the liver or biliary tract
cancers (RR 0.4, 95% CI 0.2-0.7). This result however needs
to be confirmed in larger studies, in consideration of the
small number of cases who had used oestrogen replacement
therapies and female hormones for other indications.
These results are unlikely to be explained in terms of
selection, information or confounding bias, since the catch-
ment areas of cases and controls were comparable; partici-
pation was almost complete; there is no reason to suggest
differential recall of hormone use by liver cancer cases and
controls; and as allowance for several potential confounding
factors did not notably modify the relative risk estimates.
A potential limitation of this study is its hospital-based
design (Mantel & Haenszel, 1959), with all the consequent
implications, such as the lack of information on total number
of incident liver cancers and the exclusion of cases who died
before interview. Moreover, only clinical of hepatitis was
investigated and hepatitis B serum markers were not
measured, thus precluding the possibility of adequately inves-
tigating possible interactions or viral carcinogenesis with hor-
mone use.
In conclusion, the indication emerging from this study of a
long-lasting increase in the risk of hepatocellular carcinoma
in OC users is of interest to quantify the ultimate risks and
benefits of OC use. The evidence is limited, but reassuring,
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